$437 Million is the total value of Fairmount Funds Management LLC's 27 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXSM | AXSOME THERAPEUTICS INC | $36,100,000 | -7.5% | 942,571 | 0.0% | 8.26% | -10.4% | |
| ENTA | ENANTA PHARMACEUTICALS INC | $22,182,000 | -33.6% | 469,264 | 0.0% | 5.08% | -35.7% | |
| VRDN | VIRIDIAN THERAPEUTICS INC | $10,923,000 | -37.4% | 944,092 | 0.0% | 2.50% | -39.4% | |
| OLMA | OLEMA PHARMACEUTICALS INC | $10,864,000 | -4.5% | 2,669,300 | 0.0% | 2.49% | -7.5% | |
| IOVA | IOVANCE BIOTHERAPEUTICS INC | $4,301,000 | -33.7% | 389,588 | 0.0% | 0.98% | -35.9% | |
| VRNA | VERONA PHARMA PLCsponsored ads | $3,882,000 | -16.0% | 926,602 | 0.0% | 0.89% | -18.8% | |
| TIL | INSTIL BIO INC | $3,113,000 | -57.0% | 673,905 | 0.0% | 0.71% | -58.4% | |
| ASTRIA THERAPEUTICS INC | $2,735,000 | -55.3% | 911,736 | 0.0% | 0.63% | -56.7% | ||
| ALLK | ALLAKOS INC | $461,000 | -45.0% | 147,189 | 0.0% | 0.11% | -46.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARGENX SE | 16 | Q3 2023 | 9.3% |
| AXSOME THERAPEUTICS INC | 15 | Q3 2023 | 24.6% |
| INSMED INC | 12 | Q3 2022 | 15.0% |
| ACADIA PHARMACEUTICALS INC | 12 | Q3 2022 | 15.5% |
| IOVANCE BIOTHERAPEUTICS INC | 12 | Q3 2022 | 9.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 7.2% |
| ENANTA PHARMACEUTICALS INC | 12 | Q3 2022 | 9.6% |
| ALLAKOS INC | 12 | Q3 2022 | 7.4% |
| AMARIN CORP PLC | 12 | Q3 2022 | 10.9% |
| VERONA PHARMA PLC | 12 | Q2 2023 | 11.9% |
View Fairmount Funds Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | June 30, 2023 | 17,230,540 | 20.0% |
| Olema Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| CATABASIS PHARMACEUTICALS INC | June 17, 2021 | 4,092,166 | 5.3% |
| MIRAGEN THERAPEUTICS, INC. | January 05, 2021 | 967,671 | 20.0% |
| Unum Therapeutics Inc. | July 10, 2020 | 7,482,460 | 20.0% |
View Fairmount Funds Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-16 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-04-25 |
| SC 13D/A | 2024-04-25 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
| SC 13D/A | 2024-04-01 |
View Fairmount Funds Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.